H eart failure with preserved ejection fraction (HFPEF) constitutes more than half of heart failure (HF) in older adults, and its incidence and prevalence are increasing.
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Cardiology HFPEF diagnostic guidelines. 12 All subjects had a history of systemic hypertension, left ventricular ejection fraction ≥50%, and evidence of ventricular diastolic dysfunction by catheterization or echocardiography, supplemented by neurohormonal measures if diastolic function was indeterminate. Specific exclusions related to the DASH/SRD included estimated glomerular filtration rate <30 mL/min per 1.73 m 2 and current serum potassium >5.0 mmol/L (or previous ≥6.0 mmol/L). On the basis of previous reports, 11 we estimated that 12 subjects would give >80% power to detect a 10-mm Hg reduction in clinic systolic BP and a 20% reduction in urinary 8-epi-prostaglandin F 2α -isoprostane levels (F2-isoprostanes).
The study took place over 25 days, with 2 days of testing before and after 21 days of DASH/SRD (see Figure S1 in the online-only Data Supplement for timeline). On day 1, patients presented on their habitual diet after their usual morning medications. Baseline diet was assessed with the block food frequency questionnaire. 13 Seated clinic BPs and 6-minute walk testing were performed; patients returned home on their habitual diet for ambulatory BP measurement and 24-hour urinary collection. On day 2, patients presented fasting, and before taking morning antihypertensives, they underwent vascular testing, transthoracic echocardiography, and blood sampling.
Subjects were provided all food and beverages (except water, tea, and coffee) for the DASH/SRD beginning on day 3, with a safety visit 4 to 6 days later. If orthostatic vital sign changes, overt hypovolemia, or worsening azotemia was observed, diuretics were withdrawn or reduced. Other antihypertensives were reduced or withdrawn only for systolic BP <100 mm Hg or severe orthostasis. Subjects were withdrawn for serum potassium >5.7 mg/dL (mandated) or significant worsening of renal function (investigator discretion). On days 24 and 25, patients had identical testing to days 1 and 2.
Characteristics of Study Diet and Tracking of Dietary Adherence
The study diet was prepared by research dietitians in a metabolic kitchen at the University of Michigan Clinical Research Unit. The intent was to match the DASH diet nutritional content and food types while maintaining a daily sodium intake of 50 mmol (1150 mg)/2100 kcal, the amount producing the largest BP reduction in the DASH-sodium trial. 10 Caloric content was adjusted for expected energy needs to maintain lean body mass. In patients with estimated glomerular filtration rate <60 mL/min per 1.73 m 2 , study diet potassium content was reduced from 4 to 3 g/d as suggested by the National Kidney Foundation. 14 Study food was packaged for storage, with premeal preparation (heating, etc) completed at home by the patient. Subjects were advised not to ingest nonstudy foods or beverages but were not required to consume all the provided food. Adherence was assessed with a 3-day food diary (at the midpoint) and pre-and post-DASH/SRD 24-hour urinary sodium and potassium excretion.
BP, Laboratory, Cardiovascular, and Functional Testing
Two-seated clinic BPs were obtained per Joint National Committee (Seventh Report) recommendations. 15 Ambulatory BP monitoring was performed per British Society of Hypertension guidelines 16 using the Spacelabs 90207 monitor (Spacelabs Healthcare, Issaquah, WA). Patient-reported sleep and wake times separated recordings into nighttime and daytime BPs. As in previous HF studies, the nondipping BP pattern was defined as a nighttime-to-daytime systolic BP ratio of ≥0.9.
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All laboratory testing was performed in the University of Michigan Health System clinical laboratory except urinary F2-isoprostanes, measured with a commercially available ELISA (Cayman Chemicals, Ann Arbor, MI). Transthoracic echocardiography used the Acuson Sequoia C512 (Siemens USA, Malvern, PA) and carotid-femoral pulse wave velocity the Sphygmocor tonometer (AtCor Medical, Itasca, IL). Six-minute walk testing was performed per American Thoracic Society guidelines with Borg scores for dyspnea and fatigue.
Statistical Analysis
Data are presented as the mean±SD or median (interquartile range). Analysis was performed using STATA 10.0 (StataCorp, College Station, TX). Paired t tests and Wilcoxon rank-sum tests were used for continuous and ordinal variables, respectively, with P<0.05 considered statistically significant.
Results

Patient Characteristics
The characteristics of the 14 enrolled participants (of 22 screened) are shown in Table 1 . In addition to meeting study inclusion criteria, 13 of 14 subjects fulfilled 2007 European Society of Cardiology HFPEF diagnostic guidelines (7 by catheterization and 6 via neurohormonal and echocardiographic criteria). 12 Participants were primarily obese postmenopausal women with multiple comorbidities, and most had been previously hospitalized for decompensated HFPEF.
Thirteen patients completed the study; 1 was withdrawn because of serum potassium of 5.9 mmol/L at the safety visit. This subject's electrolytes and renal function data are included in calculated pre-and post-mean values.
Study Diet and Adherence
A sample 1-day DASH/SRD study menu is shown in Table  S2 . All subjects reported excellent DASH/SRD adherence per 3-day food diaries, corroborated by increased urinary potassium excretion and halving of urinary sodium excretion from baseline in the 12 participants who were not on selfadjusted diuretic regimens (Table 2) . A comparison of caloric and major nutrient intake between baseline and DASH/SRD diet is shown in Table S3 . The mean weight loss during the study was 3.8 pounds.
BP and Medication Changes
Baseline medications and changes during the study are shown in Table S4 . All clinic and ambulatory BP recordings were adequate for analysis. In most subjects, baseline 24-hour monitoring demonstrated well-controlled BP consistent with HFPEF guidelines (systolic BP <130 mm Hg). 2 The DASH/ SRD significantly lowered clinic and 24-hour BP ( Table 3) . The number of patients with above-goal BP significantly decreased, and there was a trend toward fewer subjects with nondipping BP after DASH/SRD.
Laboratory Studies
Serum sodium and measured creatinine clearance trended lower, blood urea nitrogen increased, and serum cystatin C was unchanged ( Table 2 ). Urinary aldosterone excretion increased, but B-type natriuretic peptide and urinary F2-isoprostanes significantly declined (Table 2 and Figure, On exploratory stepwise regression, changes in urinary sodium excretion on DASH/SRD predicted urinary F2-isoprostane changes independent of baseline urinary sodium excretion and F2-isoprostane levels and weight change during the study.
Cardiovascular and Functional Studies
All patients had normal left ventricular ejection fraction by transthoracic echocardiography (69±6%; Simpson method in 11, estimated in 2). The mean left atrial diameter was 42 mm. At baseline, 6 patients had grade II and 4 had grade I diastolic dysfunction, with 2 indeterminate (because of atrial fibrillation and suboptimal Doppler signal quality, respectively) 18 
Discussion
Our study is the first to investigate the physiological effects of dietary modification in hypertensive HFPEF. As hypothesized, the DASH/SRD significantly reduced clinic BP, ambulatory BP, and arterial stiffness. Despite an expected increase in aldosterone production, urinary F2-isoprostane levels significantly declined in parallel to urinary sodium excretion after DASH/SRD.
Potential Links Among Diet, Salt-Sensitive Hypertension, and HFPEF
Dietary sodium indiscretion frequently precipitates HF decompensation, particularly in elderly patients. However, dietary sodium reduction can increase neurohormonal activation, worsen renal function, and increase hospitalizations in patients with compensated HFREF. 19 The possibility that dietary patterns contribute to HFPEF pathophysiology has not been extensively considered. In the first National Health and Nutrition Examination Survey, high-dietary sodium intake predicted incident HF only in overweight and obese respondents. 20 In a large cohort of postmenopausal women, the most common HFPEF demographic, incident HF was inversely related to DASH diet pattern adherence. 21 Hospitalized HFPEF patients instructed to reduce dietary sodium at hospital discharge were less likely to be readmitted within 30 days. 9 These studies suggest that dietary factors influence the pathogenesis of HFPEF.
More than three quarters of HFPEF patients have systemic hypertension. 1, 9 Chronic high-dietary sodium intake correlates with hypertension prevalence across disparate populations, 3 and many advocate population-based dietary sodium restriction to prevent hypertension and its complications. However, only ≈25% of normotensives and 30% to 50% of hypertensives are salt sensitive, as defined by short-term BP changes between sodium-replete and -deplete states. 4 The BP thresholds for salt sensitivity, measurement protocols, and reproducibility of the sodium-BP response vary in the literature. 4, 22 Despite these limitations, the salt-sensitive phenotype remains a useful construct to understand hypertensive cardiovascular disease. As in animal models, 5-8 independent of total BP load, salt-sensitive humans develop cardiovascular abnormalities that are implicated in HFPEF. These include left ventricular hypertrophy and diastolic dysfunction, large-artery stiffening, and endothelial dysfunction. Clinical predictors of salt-sensitive BP include advanced age, the postmenopausal state, hypertension, abdominal obesity, insulin resistance, and chronic renal insufficiency 4 ; these demographics match those in large HFPEF cohorts.
1,9
BP Effects of DASH/SRD
The magnitude of BP reduction after DASH/SRD in this study was greater than in untreated hypertensives 10 and prehypertensives, 11 comparable to adding an antihypertensive drug, 23 and occurred despite treatment with multiple antihypertensive agents in most subjects. By the end of the study, significantly more HFPEF patients met the guideline-recommended systolic BP goal. 2 Moreover, in 4 of 13 subjects, antihypertensives and diuretics were reduced shortly after starting the DASH/SRD (Table S3) .
As expected, 23 the 24-hour BP reduction was smaller than in clinic BP but still notable. The BP nondipping pattern reflects impaired renal sodium handling and tracks closely with clinically demonstrated salt-sensitive BP. 24 Nondipping BP doubles the risk of incident HF in older adults, independent of overall BP load and other clinical predictors, 25 and in HFREF patients increases cardiovascular hospitalization and death. 17 Ambulatory BP has not been reported previously in HFPEF. In this cohort, most patients were nondippers despite diuretic treatment. The DASH/SRD restored normal BP dipping in 3 subjects, consistent with the effects of dietary sodium reduction in hypertensives without HF. 
Cardiovascular and Functional Effects of DASH/SRD
The classic conceptual model of HFPEF has expanded beyond ventricular diastolic dysfunction to encompass abnormalities in multiple cardiovascular domains. In particular, increased large-artery stiffness likely contributes to exercise intolerance and dyspnea in HFPEF. In this cohort, elevated pulse pressure and carotid-femoral pulse wave velocity at baseline indicated significant large-artery stiffness. Previous studies demonstrated reduced arterial stiffness after 3 months of sodium restriction in postmenopausal women 26 and after 3 weeks of the DASH/SRD in younger subjects with clinically confirmed salt-sensitive BP. 11 Our findings are consistent with these results and were accompanied by a modest improvement in 6-minute walk distance and postexercise dyspnea.
Echocardiographic diastolic function 18 did not significantly change after the DASH/SRD. The short study duration was unlikely to produce structural myocardial changes, and standard parameters such as E/e ratio may not be accurate enough to reflect serial differences in diastolic function or filling pressures in HFPEF. 27 More recently developed measures, such as diastolic strain rate, could potentially delineate subtle changes in diastolic function with dietary modification.
Aldosterone and Oxidative Stress Effects of DASH/SRD
In salt-sensitive animals, high sodium feeding induces oxidative stress, which drives immune cell activation, perivascular inflammation, and fibrosis. [5] [6] [7] [8] In these models, maintenance of normal or low dietary sodium intake largely prevents hypertension and end-organ pathology. Dietary supplementation with potassium, magnesium, calcium, and antioxidants reduces oxidative stress, inflammation, and cardiovascular damage even if high sodium intake continues. 5, 28, 29 The DASH/SRD, low in sodium and high in potassium, magnesium, calcium, and antioxidants, reduces systemic oxidative stress in salt-sensitive humans but not in salt-resistant persons, that is, those whose BP changes little in response to sodium intake. 11, 30 Given reduced sodium and increased potassium intake, we expected that the DASH/SRD would increase aldosterone, generally viewed as a strong prooxidant stimulus. 5, 31 In saltsensitive experimental models, genomic and nongenomic mineralocorticoid effects often mediate end-organ damage. However, high mineralocorticoid levels in these animals do not cause severe adverse effects unless accompanied by elevated oxidative stress. 5, 31 In this study, urinary F2-isoprostanes did not correlate with aldosterone excretion; rather, they were closely related to the reductions achieved in urinary sodium excretion on the DASH-SRD. Our findings are consistent with a previous study in salt-sensitive humans without HF where the DASH/SRD reduced systemic oxidative stress despite more than doubling serum aldosterone levels.
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In HFREF, systemic oxidative stress predicts functional class, increases during decompensation, and decreases after HF treatment. 32, 33 In this cohort, the baseline urinary F2-isoprostane excretion was comparable to that reported in HFREF patients 32 and decreased by >30% after the DASH/SRD. In hypertensives without HF, increased systemic oxidative stress predicts reduced exercise capacity, ventricular hypertrophy and diastolic dysfunction, and endothelial dysfunction. 34, 35 Venous endothelial biopsy directly links oxidative stress and vascular dysfunction in older adults with metabolic syndrome, a demographic precursor to HFPEF. 36 In addition, heightened oxidative stress is present in the myocardium of HFPEF patients and is thought to drive cytokine production and myofibroblast differentiation. 37 These observations imply that oxidative stress is a key etiological component of HFPEF; our findings suggest a potential method to ameliorate this mechanism.
Safety
The DASH/SRD has not been studied previously in HF or chronic kidney disease (100% of our cohort). Four patients developed orthostasis requiring medication adjustment, and 1 was withdrawn for elevated serum potassium despite DASH/SRD modification as suggested by the National Kidney Foundation.
14 In contrast to a previous study of sodium reduction in HFREF, 19 where high-dose loop diuretics were continued, we adjusted diuretics at a safety visit based on clinical status. Although no subject was removed from participation because of renal dysfunction, serum urea nitrogen levels increased and creatinine clearance trended lower after DASH/ SRD (Table 2 ). These changes are consistent with plasma volume reduction, also suggested by the modest weight loss on the isocaloric study diet. The lack of change in cystatin C implies that the DASH/SRD did not cause renal injury. Nonetheless, significant renal dysfunction can occur during sodium restriction in HF, 19 and this short-term study highlights the importance of close renal monitoring during dietary modification.
Study Limitations
Our results are hypothesis generating and not necessarily generalizable to all HFPEF patients, such as those with nonhypertensive pathogenesis or different demographics. The study group was enriched in characteristics that predict salt sensitivity (eg, advanced age, diabetes mellitus, obesity, renal insufficiency, and postmenopausal state) 4 and, as such, closely resembled patients in large HFPEF cohort studies. 1, 9 In this small cohort, we were unable to determine whether specific factors contributed disproportionately to the salt-sensitive phenotype. Because extracardiac comorbidities contribute to the pathophysiology of HFPEF, 38 defining these relationships is an important area for future research.
In this pilot study, we used dietary intervention to reveal similarities between the salt-sensitive phenotype and hypertensive HFPEF. Our study is analogous to an early study of exercise training in HFPEF demonstrating safety and proof of concept 39 that subsequently led to larger randomized trials. 40 To place our results in context, the effect sizes for BP and oxidative stress were consistent with previous DASH diet studies in non-HF cohorts, which showed no clinic or ambulatory BP changes with habitual or control diets. 41, 42 In particular, the observed difference in 24-hour BP in this study is unlikely to be because of a placebo effect. 23, 41 Nonetheless, our findings should now be verified and expanded upon in the context of a randomized trial.
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We do not know which specific DASH/SRD components (eg, sodium reduction, increased potassium, or increased antioxidant intake) contributed to the observed effects. We did not hospitalize subjects to formally control dietary intake. However, we provided all food and beverages for the DASH/ SRD, and urinary measures and food diaries indicated excellent dietary adherence. It is unknown whether our short-term results could be sustained in a cohort with complete freedom of food choice. Future, long-term studies could include ongoing dietary education and other measures to support adherence.
Perspectives
HFPEF is a major public health challenge currently without evidence-based therapy, largely because of incomplete understanding of its pathophysiology. Experimental models and HFPEF epidemiology suggest that dietary patterns and salt-sensitive hypertension play important roles. In this cohort of patients with hypertensive HFPEF, 3 weeks of the sodium-restricted DASH diet significantly reduced clinic and ambulatory BP, arterial stiffness, and oxidative stress. These observations are characteristic of salt-sensitive hypertension, a phenotype present in nearly all animal models of HFPEF. Further dietary modification studies could provide insights into the development and progression of hypertensive HFPEF.
What Is New?
• Recent studies implicate oxidative stress and vascular dysfunction as key factors in human hypertensive HFPEF.
• No previous dietary modification studies have been reported in hypertensive HFPEF.
What Is Relevant? • Animal models of HFPEF display a salt-sensitive phenotype, with dietinduced oxidative stress driving perivascular inflammation and fibrosis.
• The demographics and comorbidities commonly found in HFPEF are strongly associated with BP salt sensitivity.
